Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8713187 | 0.85 | NR3C1 (0.52) | ALDH1A1NR3C1HTTLMNASMN1; SMN2 | |
| SCHEMBL10294170 | 0.81 | NR3C2 (0.44) | ALDH1A1NR3C1HTTLMNASMN1; SMN2 | |
| SCHEMBL10294719 | 0.80 | HPGD (0.56) | ALDH1A1HTTLMNASMN1; SMN2ADRA2A | |
| SCHEMBL4377344 | 0.76 | HDAC4 (0.48) | ALDH1A1HTTLMNASMN1; SMN2ADRA2A | |
| SCHEMBL10589236 | 0.76 | NR3C1 (0.41) | ALDH1A1NR3C1HTTLMNASMN1; SMN2 | |
| SCHEMBL10294637 | 0.74 | POLB (0.57) | ALDH1A1LMNAHPGDMAPTHTR7 | |
| SCHEMBL10191952 | 0.74 | HPGD (0.53) | ALDH1A1HTTLMNASMN1; SMN2BRD4 | |
| SCHEMBL13001968 | 0.74 | HPGD (0.53) | ALDH1A1HTTLMNASMN1; SMN2BRD4 | |
| SCHEMBL11409417 | 0.73 | HTT (0.54) | ALDH1A1NR3C1HTTLMNASMN1; SMN2 | |
| SCHEMBL27389810 | 0.73 | HDAC4 (0.46) | ALDH1A1LMNASMN1; SMN2MAPTHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | ALDH1A1 213/4885NR3C1 462/4885HTT 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.